Skip to main content

Table 3 Univariate analysis in terms of OS (overall survival) and EFI (event free survival) with correction for competing risks and on the total population

From: APE1 and NPM1 protect cancer cells from platinum compounds cytotoxicity and their expression pattern has a prognostic value in TNBC

Variable   SHR 95% C.I. p value
EFI
 NPM1 Continuous 0.99 0.98–1.00 0.147
 NPM1 nucleolus No 1   
Yes 1.83 0.79–4.27 0.161
 NPM1 with cut-off > 50% 1   
≤50% 1.43 0.69–3.02 0.334
 nAPE1 Continuous 0.99 0.98–1.00 0.344
 cAPE1 Continuous 1.01 0.99–1.02 0.149
 Tumor size 1 1   
2 1.35 0.58–3.14 0.491
3 or 4 3.48 0.79–15.44 0.100
 Nodal status Negative 1   
Positive 2.05 0.92–4.58 0.079
 Neo/Adj Anthracyclines No 1   
Yes 1.06 0.47–2.39 0.886
 Neo/Adj Taxanes No 1   
Yes 0.82 0.39–1.69 0.585
OS   HR 95% C.I. p value
 NPM1 nucleolus No 1   
Yes 1.37 0.59–3.20 0.464
 NPM1 with cut-off > 50% 1   
≤50% 1.25 0.61–2.57 0.541
 nAPE1 Continuous 1 0.99–1.01 0.767
 cAPE1 Continuous 1 0.99–1.01 0.553
 Tumor size 1 1   
2 1.73 0.73–4.11 0.214
3 or 4 12.59 4.30–36.84 < 0.001
 Nodal status Negative 1   
Positive 1.47 0.68–3.17 0.328
 Neo/Adj Anthracyclines No 1   
Yes 0.45 0.22–0.91 0.026
 Neo/Adj Taxanes No 1   
Yes 0.50 0.24–1.02 0.055
  1. Tumor size was confirmed as the most important prognostic factor. nAPE1 (nuclear APE1), cAPE1 (cytoplasmic APE1) NPM1 (NPM1low vs NPM1high), HR (hazard ratio), SHR (subdistribution hazard ratio)